atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
According to the company, the design of the camera was developed to meet the needs of general healthcare providers, including primary care, optometry, retail health clinics and home health settings, and ensure accessibility and practicality in these environments.
Read more…
The NHS is to be allowed to hire physician associates (PA) from Ghana, Zimbabwe and Bangladesh, despite concerns over the quality of their training.
Doctors have been in revolt over the plan to increase the number of PAs and AAs…
Attendees
Sponsors and Exhibitors
AI Training for Doctors Workshops
Contact us